Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Status:
Recruiting
Trial end date:
2029-04-30
Target enrollment:
Participant gender:
Summary
This study will enroll participants with urothelial cancer (UC). UC can include cancer of the
bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study
will try to find out if the drugs disitamab vedotin with pembrolizumab works better than
platinum-containing chemotherapy to treat patients with UC. This study will also test what
side effects happen when participants take these drugs together. A side effect is anything a
drug does to the body besides treating the disease.
Participants in this study will have cancer that has spread through the body (metastatic) or
spread near where it started (locally advanced).
In this study, there are 2 different groups. Participants will be assigned to a group
randomly. Participants in the disitamab vedotin arm will get the study drug disitamab vedotin
once every two weeks and pembrolizumab once every 6 weeks. Participants in the standard of
care arm will get gemcitabine once a week for 2 weeks with either cisplatin or carboplatin
once every 3 weeks.